Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Decrease in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) saw a large drop in short interest in March. As of March 13th, there was short interest totaling 300 shares, a drop of 97.1% from the February 26th total of 10,300 shares. Based on an average daily volume of 1,769,827 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the stock are short sold.

Bioxytran Price Performance

Shares of OTCMKTS BIXT traded up $0.00 during mid-day trading on Thursday, hitting $0.04. 12,300 shares of the stock traded hands, compared to its average volume of 392,500. The company has a market cap of $4.95 million, a PE ratio of -1.46 and a beta of 2.14. Bioxytran has a twelve month low of $0.03 and a twelve month high of $0.23. The firm has a 50 day simple moving average of $0.05 and a two-hundred day simple moving average of $0.06.

Bioxytran Company Profile

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.